公开(公告)号：US20240327334A1

公开(公告)日：2024-10-03

申请号：US18390287

申请日：2023-12-20

申请人： Enanta Pharmaceuticals, Inc.

发明人： Xuri GAO ,  Bin WANG ,  Hui CAO ,  Jiajun ZHANG ,  Yuk Ming SIU ,  Jiang LONG ,  Wei LI ,  Matthew C. RHODES ,  Xuechao XING ,  Jianming YU ,  Scott MITCHELL ,  Yat Sun OR

IPC分类号： C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/40

CPC分类号： C07C233/56 ,  A61K31/166 ,  A61K31/277 ,  A61K31/337 ,  A61K31/365 ,  A61K31/381 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/662 ,  A61P31/14 ,  C07C243/30 ,  C07C255/46 ,  C07C255/66 ,  C07D205/04 ,  C07D207/16 ,  C07D209/52 ,  C07D209/56 ,  C07D213/40 ,  C07D215/12 ,  C07D231/08 ,  C07D231/12 ,  C07D231/56 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D263/34 ,  C07D265/02 ,  C07D277/28 ,  C07D295/185 ,  C07D305/08 ,  C07D307/58 ,  C07D333/20 ,  C07D333/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/4015

摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240325326A1

公开(公告)日：2024-10-03

申请号：US18583392

申请日：2024-02-21

申请人： University of Kentucky Research Foundation

发明人： Matthew S. Gentry ,  Ramon C. Sun ,  Ronald C Bruntz ,  Christopher M Waters

IPC分类号： A61K31/167 ,  A61K31/166 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/428 ,  A61K31/433 ,  A61K31/436 ,  A61K31/47 ,  A61K31/5375 ,  A61P11/00

CPC分类号： A61K31/167 ,  A61K31/166 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/428 ,  A61K31/433 ,  A61K31/436 ,  A61K31/47 ,  A61K31/5375 ,  A61P11/00 ,  C07K2317/569

摘要： A method for treating pulmonary fibrosis (PF) is provided. The method includes administering to a subject in need thereof an effective amount of a compound selected from the group consisting of a glycogen phosphatase inhibitor, an acid alpha-glucosidase (GAA) inhibitor, a glycogen synthase (GYS) inhibitor, a glycogen phosphorylase (GP) inhibitor, and combinations thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240307340A1

公开(公告)日：2024-09-19

申请号：US18263059

申请日：2022-01-19

申请人： INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Seok Ju PARK

IPC分类号： A61K31/235 ,  A61K31/166 ,  A61P17/06 ,  A61P35/00 ,  A61P37/06

CPC分类号： A61K31/235 ,  A61K31/166 ,  A61P17/06 ,  A61P35/00 ,  A61P37/06

摘要： The present invention discloses the use of benzene derivatives as immunosuppressants. The benzene derivatives as immunosuppressants are represented by Formula 1:




wherein R is a linear alkyl group, a branched alkyl group or an alkyl group containing one or more carbon-carbon double bonds, X is an amide or ester group, and Y is a halo, methoxy, ethoxy, hydroxyl or nitro group. The benzene derivatives are used in the preparation of immunosuppressive medicaments. The benzene derivatives are effective for treating T cell-mediated immune diseases, for example, for preventing and treating rejection after organ and bone marrow transplantation and treating T cell-mediated autoimmune diseases, psoriasis, multiple sclerosis, rheumatoid arthritis, insulin-dependent diabetes mellitus, specific hemolytic anemia, ulcerative colitis, myasthenia gastrica, glomerulonephritis, Guillain-Barre syndrome, and allergic diseases such as allergic asthma and atopy due to their ability to inhibit the proliferation of T lymphocytes.

公开(公告)号：US20240173274A1

公开(公告)日：2024-05-30

申请号：US18518127

申请日：2023-11-22

申请人： SpringWorks Therapeutics Inc.

发明人： Uchenna H. ILOEJE ,  Abraham J. LANGSETH ,  Todd Webster SHEARER

IPC分类号： A61K31/166 ,  A61K9/00 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

CPC分类号： A61K31/166 ,  A61K9/0053 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

摘要： The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.

公开(公告)号：US20240141356A1

公开(公告)日：2024-05-02

申请号：US18466254

申请日：2023-09-13

申请人： The Hong Kong University of Science and Technology

发明人： Kai LIU ,  Xu WANG ,  Chao YANG

IPC分类号： C12N15/113 ,  A61K31/166 ,  A61K31/433 ,  A61K45/06 ,  A61P25/00 ,  C12N5/0793 ,  C12N9/22

CPC分类号： C12N15/1137 ,  A61K31/166 ,  A61K31/433 ,  A61K45/06 ,  A61P25/00 ,  C12N5/0619 ,  C12N9/22 ,  C12N2310/122 ,  C12N2310/20

摘要： The subject invention pertains to a method for promoting axon regeneration in a subject with central nervous system injury. More specifically, the method comprises activating STAT1 signaling, cGAS-STING pathway, or a combination thereof by administering IFNγ and inhibiting the expression or function Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) inhibitor; or administering a STING agonist.

公开(公告)号：US11951085B2

公开(公告)日：2024-04-09

申请号：US17488591

申请日：2021-09-29

申请人： BIOGEN CHESAPEAKE LLC

发明人： Sven Martin Jacobson

IPC分类号： A61K31/64 ,  A61K9/00 ,  A61K31/166 ,  A61K31/18 ,  A61K31/451 ,  A61K47/26 ,  A61P9/10

CPC分类号： A61K31/18 ,  A61K9/0019 ,  A61K31/166 ,  A61K31/451 ,  A61K31/64 ,  A61K47/26

摘要： The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.

公开(公告)号：US20240058321A1

公开(公告)日：2024-02-22

申请号：US18269537

申请日：2022-11-02

申请人： SEMMELWEIS EGYETEM ,  KINETO LAB KFT. ,  EÖTVÖS LORÁND TUDOMÁNYEGYETEM ,  TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT

发明人： József TÍMÁR ,  Balázs HEGEDUS ,  Marcell BARANYI ,  Eszter MOLNÁR ,  József TÓVÁRI ,  Ivan RANDELOVIC ,  András PERCZEL ,  György KESERU ,  László BUDAY

IPC分类号： A61K31/4709 ,  A61K31/166 ,  A61K31/4184 ,  A61K31/4545 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5513 ,  A61P35/00

CPC分类号： A61K31/4709 ,  A61K31/166 ,  A61K31/4184 ,  A61K31/4545 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5513 ,  A61P35/00

摘要： The invention relates to cancer biology, more specifically to the treatment of KRAS mutant cancers. A potent cancer therapy is provided by the combination of a farnesyl transferase inhibitor compound and a KRAS inhibitor compound.

公开(公告)号：US20240058282A1

公开(公告)日：2024-02-22

申请号：US18357988

申请日：2023-07-24

申请人： SpringWorks Therapeutics Inc.

发明人： Uchenna H. Iloeje ,  Abraham J. Langseth ,  Todd Shearer

IPC分类号： A61K31/166 ,  A61K9/00 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

CPC分类号： A61K31/166 ,  A61K9/0053 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

摘要： The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11896564B2

公开(公告)日：2024-02-13

申请号：US17264924

申请日：2019-08-15

申请人： PHARMACYL AB

发明人： Gunnar Hedlund ,  Anders Björk

IPC分类号： A61K31/166 ,  A61P1/04 ,  A61K45/06

CPC分类号： A61K31/166 ,  A61K45/06 ,  A61P1/04

摘要： A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation. The combination of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and 5-ASA agent and use of such combination. A kit-of-parts and a pharmaceutical composition comprising such a combination.

公开(公告)号：US11883375B2

公开(公告)日：2024-01-30

申请号：US18334518

申请日：2023-06-14

申请人： SpringWorks Therapeutics Inc.

发明人： Uchenna H Iloeje ,  Abraham J Langseth ,  Todd Shearer

IPC分类号： A61K31/166 ,  A61P35/00 ,  A61K45/06 ,  A61K9/00 ,  A61K31/216 ,  A61P25/00

CPC分类号： A61K31/166 ,  A61K9/0053 ,  A61K31/216 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

摘要： The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.